CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Details 4) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014	Sep. 09, 2014
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments	$ 600	$ 1,100
Estimated fair value of debt instruments
Reduction in basic and diluted net loss per share	$ (0.02)	$ (0.05)
Convertible notes due 2021
Estimated fair value of debt instruments
Interest rate (as a percent)	2.50%	2.50%		2.50%
Principal amount	$ 345,000	$ 345,000	$ 345,000	$ 345,000
Level 3 | Contingent consideration
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Balance at the beginning of the period		17,595
Unfavorable contract assumed	661	661	3,343
Balance at the end of the period	15,381	15,381
Decrease in fair value of the unfavorable contract assumed	1,200	3,000
Level 3 | Contingent consideration | Interest Expense.
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Change in fair value		269
Net accretion value adjustments		1,090
Level 3 | Contingent consideration | Selling general and administrative expense
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Change in fair value	1,500	(2,951)
Net accretion value adjustments		(2,986)
Level 3 | Contingent consideration | Royalties Paid
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments		(318)
Level 3 | Contingent consideration | Zipsor
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Balance at the beginning of the period		1,800
Balance at the end of the period	1,575	1,575
Level 3 | Contingent consideration | Zipsor | Interest Expense.
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments		124
Level 3 | Contingent consideration | Zipsor | Selling general and administrative expense
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments		(349)
Level 3 | Contingent consideration | Lazanda
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Balance at the beginning of the period		11,209
Balance at the end of the period	11,751	11,751
Level 3 | Contingent consideration | Lazanda | Interest Expense.
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments		597
Level 3 | Contingent consideration | Lazanda | Selling general and administrative expense
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments		263
Level 3 | Contingent consideration | Lazanda | Royalties Paid
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments		(318)
Level 3 | Contingent consideration | CAMBIA
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Balance at the beginning of the period		1,243
Balance at the end of the period	1,394	1,394
Level 3 | Contingent consideration | CAMBIA | Interest Expense.
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments		100
Level 3 | Contingent consideration | CAMBIA | Selling general and administrative expense
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments		51
Fair Value | Level 2 | Convertible notes due 2021
Estimated fair value of debt instruments
Estimated fair value of debt	$ 437,100	$ 437,100	$ 375,200